THE AUSTRIAN CENTRE
OF INDUSTRIAL BIOTECHNOLOGY

acib is an international competence centre, developing new, environmentally friendly, economically and technically advanced processes for the biotechnological, pharmaceutical and chemical industry – all of them modelled on nature. acib is bridging the gap between academic research and producing industry. The big advantage for acib partner organisations is the possibility to translate scientific results into concrete processes and product by using scientific know-how, academic infrastructure or industrial networks. Our platform offers tailor-made solutions for our stakeholders from Academia, Industry and Investors.

 LATEST BLOG ARTICLES
  • Carbon dioxide in a circular economy
  • Time for real-time monitoring of biopharma production
  • Open innovation – a case of “nothing ventured, nothing gained”
  • Gene switch in yeast discovered
  • Computer aided design of separation processes  in pharmaceutical production
  • Getting more oxygen into your system – an innovative way of process intensification
  • Glycobiology meets chemistry to generate tailor-made offspring
  • Project proposal writing and some common pitfalls
  • Plant Microbiota and their natural antibiotic resistances
  • Key for citric acid production discovered
  • Carbon dioxide in a circular economy

    Carbon dioxide (CO2) emission is a massive problem for our climate; this is well-known. We urgently need measures to prevent earth from the big collapse. Where do we find them? Biotechnology offers some interesting solutions.

    Read more

  • Time for real-time monitoring of biopharma production

    While currently most production processes for biopharmaceuticals are assessed by laboriuos and time-consuming off-line analytics, a new process enables the monitoring of such processes in real-time. Sensors  combined with  mathematical models deliver information on the quality and quantity of the product, as well as on content and profile impurities. This allows an instant monitoring of processes, making processes safer, faster, cheaper and more efficient.

    Read more

  • Open innovation – a case of “nothing ventured, nothing gained”

    The modern business world is using a new buzzword: “Open innovation”. What does it mean? How “open” do we need to be? What could be the benefit? And what does it look like in reality?

    Read more

  • Gene switch in yeast discovered

    Scientists from the Department of Biotechnology at the University of Natural Resources and Life Sciences (BOKU) Vienna and the Austrian Centre of Industrial Biotechnology (acib) discovered a gene switch in yeast, that was able to change twelve genes – and thereby the metabolic process of yeast as a whole. This work explains evolutionary events that happened more than 120 million years ago. The results have recently been published in the scientific journal Nature Communications and have the potential to be used in the food and feed industry and for the production of bio fuels and new building blocks for bioplastics.

    Read more

  • Computer aided design of separation processes in pharmaceutical production

    Have you ever thought about how drugs are manufactured? They are often produced by microorganisms which secret them into their environment: a soup of media, the target drug and waste that must be eliminated. In the pharmaceutical industry, people use chromatography columns to purify the medication. This process is used for more than a century for the separation of compounds. One may think that everything should be already known for such a well-established process. Yet, acib researchers found out recently that already the connecting tubes and valves affect the quality of the separation process and – in the end – product quality.

    Read more

  • Getting more oxygen into your system – an innovative way of process intensification

    More efficiency, more quality, more process safety, less costs, less waste – these are the target specifications of each and every production process in chemical industry. It seems quite ambitious to meet all these requirements, but a new key word has entered the engineering world: process intensification!

    Read more

  • Glycobiology meets chemistry to generate tailor-made offspring

    An interdisciplinary team of scientists is pioneering the development of synthetic glycobiology and trains 15 young researchers in the enabling technologies that underpin the development and exploitation of glycoscience: An exciting topic that promises to bring innovative solutions for the future!

    Read more

  • Project proposal writing and some common pitfalls

    Research funding is a highly competitive process and only a small fraction of applicants get the grant in the end. EU-Horizon 2020, with almost 80 billion Euros the largest research program worldwide, has an average success rate of only 14%. What is the secret of success of those, who have made it? 

    Read more

  • Plant Microbiota and their natural antibiotic resistances

    Antibiotic-resistant bacteria are not only restricted to clinical environments, nor do they always pose an immediate danger for humans. Various environmental niches are occupied by complex microbial communities that also include members that can carry one or different antibiotic resistances. The plant microbiome often harbors highly competitive microorganisms that can shield of pathogens and contribute to the host’s health. In their latest study researchers from acib-partner TU Graz have focused on antibiotic resistances in a common salad plant and found that the indigenous enterobacterial community contributes to the highly interesting profile.

    Read more

  • Key for citric acid production discovered

    The responsible transport gene that allows the production of lemon acid in large quantities was recently discovered. A breakthrough!

    Read more

COMPANY PROFILE AND OWNERS

acib is an industrially oriented private limited company with a non-profit orientation. It is publicly owned by:

K2 RESEARCH CENTRE

acib is funded as a K2 research centre in the framework of FFG COMET funding (Competence Centres for Excellent Technologies) by BMVIT, BMWF, and the provinces of Styria, Vienna, Lower Austria and Tyrol. The COMET programme is processed via FFG. 18 scientific partners are involved in the implementation of the acib COMET programme, which is co-funded by 53 industrial partners.

More about COMET



Innovations from Nature 1
Innovations from Nature 4
Innovations from Nature 5
Innovations from Nature 2
Innovations from Nature 3
Innovations from Nature 6